SOUTH SAN FRANCISCO, Calif. - Vistagen Therapeutics (VTGN), a clinical-stage biopharmaceutical company with a market ...
As shares of Boston-based Vertex shot higher on the news of its non-opioid pill, Journavx, we took a look at investment in ...
Dr. Sanjay Gupta said Tuesday that the approval of a new non-opioid pain medication is “a pretty big deal.” “This is a pretty ...
These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...
The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx ...
Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ Suzetrigine, sold as twice-daily Journavx, a non-addictive prescription drug for ...
Vertex Pharmaceuticals ( VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and ...
The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.
Every year, thousands of people die from overdosing on opioids in the United States. But a new non-opioid pain medication, ...
The Food and Drug Administration (FDA) is hoping a newly approved non-opioid pain medication could help save lives. Dr.
The opioid epidemic continues to affect hundreds of thousands of people, but there may be hope for the future with a new, non ...
The first shot taken at Medicaid, likely UnitedHealthcare coverage for Vertex's pain drug, and Optum’s wellness visit ad.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback